Li et al. evaluate the immunogenicity and safety of the CoronaVac inactivated COVID-19 vaccine in elderly patients with underlying medical conditions in China. Most patients show comparable neutralizing antibody and SARS-CoV-2-specific T cell responses to healthy controls, and no serious adverse effects are seen.
- Chunmei Li
- Hanfang Bi
- Liang Zhang